Ace Therapeutics is an innovative CRO company focusing in early drug discovery services from target validation to preclinical candidate identification and efficacy evaluation, with strong capabilities and technologies in the stroke field.
Our goal is to help pharmaceutical companies complete their research programs faster and more successfully, and find effective therapies for stroke.
View DetailsAce Therapeutics is committed to the preclinical phase of stroke drug development, covering everything from model construction, target identification to preclinical candidates and beyond with the flexibility required. We offer a broad portfolio of services and a global network of partners that enable us to provide end-to-end services for small molecule and biomolecule drug discovery in stroke.
At Ace Therapeutics, we are dedicated to pushing the boundaries of scientific research and supporting drug development in multiple therapeutic areas within the field of preclinical stroke research.
We provide customized models, target identification, and drug efficacy assessment for ischemic stroke research to improve the understanding of the pathomechanisms of ischemic stroke and the development of therapeutics.
Our approach enables the detection of nuanced responses in animal models, providing clear insight into the efficacy and safety of novel hemorrhagic stroke therapies.
Ace Therapeutics is equipped with advanced facilities and resources to support TIA research projects. We provide highly predictive TIA models, carefully executed assessments, and detailed observational measurements to determine the effects of your novel TIA therapy.
Ace Therapeutics has a proven, full-service model that has been delivering quality results for years, giving your stroke trial a competitive edge. The Ace Therapeutics team supports the development of therapeutics for the treatment of stroke through the use of our in-house resources including: